Laboratory Corp of America Holdings (LH)

153.74
0.17 0.11
NYSE : Health Care
Prev Close 153.91
Open 154.02
Day Low/High 153.30 / 154.51
52 Wk Low/High 119.51 / 164.22
Volume 371.23K
Avg Volume 665.90K
Exchange NYSE
Shares Outstanding 101.80M
Market Cap 15.73B
EPS 7.10
P/E Ratio 21.65
Div & Yield N.A. (N.A)

Latest News

Short Interest Decreases By 23.8% For LH

Short Interest Decreases By 23.8% For LH

The most recent short interest data has been released for the 07/31/2017 settlement date, which shows a 630,218 share decrease in total short interest for Laboratory Corporation of America Holdings , to 2,022,387, a decrease of 23.76% since 07/14/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

LabCorp To Acquire Chiltern For Approximately $1.2 Billion In Cash, Advancing Its Leadership In Drug Development

LabCorp To Acquire Chiltern For Approximately $1.2 Billion In Cash, Advancing Its Leadership In Drug Development

LabCorp® (NYSE:LH), a leading global life sciences company, and Chiltern, a specialty CRO, announced today that LabCorp will acquire Chiltern pursuant to a definitive agreement with Chiltern's shareholders in an...

LabCorp Announces Record Results In The Second Quarter Of 2017 And Increases 2017 Guidance

LabCorp Announces Record Results In The Second Quarter Of 2017 And Increases 2017 Guidance

LabCorp ® (or the "Company") (NYSE: LH) today announced results for the second quarter ended June 30, 2017, and increased 2017 guidance.

LabCorp Introduces New ADAMTS13 Test For Rare Life-Threatening Blood Clot Disorder

LabCorp Introduces New ADAMTS13 Test For Rare Life-Threatening Blood Clot Disorder

LabCorp® (NYSE: LH) has begun offering its new, proprietary ADAMTS13 test to distinguish diseases characterized by life-threatening, acute thrombotic microangiopathy (TMA).

Bill Hanlon, Ph.D., Chief Development Officer And Head Of Global Regulatory Affairs, Covance (Photo: Business Wire)

Bill Hanlon, Ph.D., Chief Development Officer And Head Of Global Regulatory Affairs, Covance (Photo: Business Wire)

LabCorp® (NYSE: LH), a leading global life sciences company, announced today that the National Evaluation System for health Technology Coordinating Center (NESTcc) has appointed William (Bill) Hanlon, Ph.

LabCorp And Novant Health Extend Laboratory Services Agreement

LabCorp And Novant Health Extend Laboratory Services Agreement

LabCorp® (NYSE: LH) and Novant Health have agreed to a multi-year extension of their Technical Services Agreement, which was first implemented in 2012.

Conversion Right Triggered For LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021

Conversion Right Triggered For LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021

LabCorp® (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below.

Walgreens And LabCorp Collaborate To Bring Patient Service Centers For Laboratory Testing To Select Walgreens Stores

Walgreens and LabCorp® (NYSE: LH) today announced a collaboration through which LabCorp will develop and operate patient service centers within select Walgreens stores.

(Photo: Business Wire)

LabCorp® (NYSE:LH), a leading global life sciences company, announced today that its Covance Drug Development (Covance) business will extend its capabilities in precision medicine by opening a dedicated,...

Coalition For Access To Prenatal Screening Announces Clinical Advisory Board

Board to provide independent medical perspective on noninvasive prenatal screening

LabCorp Exclusively Launches Sera Prognostics' PreTRM Test To Assess For Risk Of Preterm Birth

LabCorp® (NYSE: LH) today announced the nationwide availability of the PreTRM® test.

LabCorp Is Scheduled To Present At The Bank Of America Merrill Lynch 2017 Health Care Conference

LabCorp® (NYSE: LH) today announced it will participate at the Bank of America Merrill Lynch 2017 Health Care Conference.

LabCorp Completes Acquisition Of Pathology Associates Medical Laboratories

LabCorp® (NYSE:LH) has completed the acquisition of Pathology Associates Medical Laboratories (PAML) from former owners Providence Health & Services (Providence) and Catholic Health Initiatives (CHI).

LabCorp To Webcast Its Annual Meeting Of Shareholders

LabCorp® (NYSE: LH) today announced that its Annual Meeting of Shareholders will be webcast live beginning May 11, 2017 at 9:00 a.

LabCorp Enhances VistaSeq Hereditary Cancer Test Portfolio With Addition Of New Panels And New Genes That Can Be Assessed

LabCorp® (NYSE: LH) today announced a significant enhancement to its proprietary VistaSeq SM Hereditary Cancer portfolio, with ten new test panels focusing on the risk of specific hereditary cancer syndromes.

LabCorp's Acquisition Of Pathology Associates Medical Laboratories Clears Antitrust Review

LabCorp® (NYSE: LH) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or HSR Act, applicable to LabCorp's acquisition of Pathology Associates Medical Laboratories,...

LabCorp Completes Acquisition Of Assets Of Mount Sinai Health System Clinical Outreach Laboratories

LabCorp ® (NYSE: LH), a leading global life sciences company, has completed the previously announced acquisition of assets of the Mount Sinai Health System Clinical Outreach Laboratories.

Good, the Bad and the Ugly; What Troubles Me: Doug Kass' Views

Good, the Bad and the Ugly; What Troubles Me: Doug Kass' Views

Doug Kass shares his thoughts on Facebook, Allergan and Eli Lilly.

LabCorp To Exclusively Offer The M3 Checklist, A Multi-Condition Mental Health Screening Tool

LabCorp ® (NYSE:LH) and M-3 Information, LLC today announced the nationwide availability through LabCorp of the peer-reviewed, clinically validated M3 Checklist assessment for mental illness.

Laboratory Corporation Of America® Holdings Announces 2017 First Quarter Results And Updates 2017 Guidance

Laboratory Corporation of America ® Holdings (LabCorp ® or the "Company") (NYSE: LH) today announced results for the first quarter ended March 31, 2017, and updated 2017 guidance.

Covance To Expand Large-Molecule Development Capabilities In The UK

Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH), a leading global life sciences company, announced today that its Covance Drug Development (Covance) business will expand its biopharmaceutical...

Conversion Right Triggered For LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021

Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below.

LabCorp Commends Reps. Dr. Bucshon, DeGette For Releasing Bipartisan Discussion Draft Of the Diagnostic Accuracy And Innovation Act (DAIA)

Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:LH), a leading global life sciences company, today issued the following statement regarding a discussion draft of the Diagnostic Accuracy and Innovation...

Gary Huff (Photo: Business Wire)

Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:LH), a leading global life sciences company, today announced that Gary Huff is being promoted to CEO of LabCorp Diagnostics, one of the company's two...

LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 To Accrue Contingent Interest

Laboratory Corporation of America ® Holdings (LabCorp ®) (NYSE: LH) announced today that for the period of March 12, 2017 to September 11, 2017, its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon...

LabCorp Is Scheduled To Present At The 2017 Barclays Global Healthcare Conference

Laboratory Corporation of America ® Holdings (LabCorp ®) (NYSE: LH) today announced it will participate at the 2017 Barclays Global Healthcare Conference.

LabCorp Is Scheduled To Present At The 38th Annual Raymond James Institutional Investors Conference

Laboratory Corporation of America ® Holdings (LabCorp ®) (NYSE: LH) today announced it will participate at the 38 th Annual Raymond James Institutional Investors Conference.